# Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

> **NCT01103089** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 10 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01103089
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103089, "Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01103089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*